What Researchers Did
Researchers reviewed the pathophysiological mechanisms and immunological aspects of gaseous therapies, including nitric oxide, carbon monoxide, and hyperbaric oxygen, as potential adjunctive treatments for severe malaria.
What They Found
Malaria affects over 200 million people globally each year, causing 584,000 deaths, with mortality rates remaining high at 8% in children and 15% in adults even with current treatments. These rates escalate to 18% and 30% for cerebral malaria, highlighting the need for adjunctive therapies that modulate pathophysiological processes, such as gaseous treatments that alter vascular endothelium dysfunction and modulate host immune response.
What This Means for Canadian Patients
While malaria is not endemic in Canada, Canadians traveling to affected regions could benefit from advancements in adjunctive therapies for severe malaria. Exploring treatments like gaseous therapies could potentially improve outcomes and reduce mortality for Canadian patients who contract severe malaria abroad.
Canadian Relevance
This review article has no direct Canadian connection as it focuses on severe malaria, a disease not endemic to Canada.
Study Limitations
As a review, this study's conclusions are based on existing literature, and it highlights that current gaseous therapies lack unequivocal evidence for improving patient clinical status.